Ascendis Pharma A/S
ASND
189 hedge funds and large institutions have $9.19B invested in Ascendis Pharma A/S in 2024 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 51 reducing their positions, and 33 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 51
21% more capital invested
Capital invested by funds: $7.61B → $9.19B (+$1.58B)
18% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 33
2% more funds holding
Funds holding: 185 → 189 (+4)
0% more funds holding in top 10
Funds holding in top 10: 16 → 16 (0)
0.31% less ownership
Funds ownership: 105.66% → 105.35% (-0.31%)
7% less call options, than puts
Call options by funds: $48.3M | Put options by funds: $51.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$131M |
| 2 |
Millennium Management
New York
|
+$48.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$40.8M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$33.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$203M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$71.7M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$32.5M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$31M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.1M |
ASND Hedge Fund Activity: Q1 2024 in Review
189 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2024, worth a combined $9.19B — up 21% from $7.61B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ASND positions and 33 closed out — a net gain of 6 holders — while 73 added to existing stakes and 51 trimmed.
The largest buyer was Franklin Resources, adding an estimated $131M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $203M.
- 189 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2024, up from 185 in Q4 2023.
- Funds reported $9.19B of Ascendis Pharma A/S stock for Q1 2024, up 21% quarter-over-quarter.
- 39 funds opened new Ascendis Pharma A/S positions in Q1 2024 and 33 closed out, a net change of +6 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2024 was Franklin Resources, an estimated $131M added.
- The largest Ascendis Pharma A/S seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $203M sold.
Based on aggregated 13F filings for Q1 2024.